Meropenem 1000 mg
Meropenem is a broad-spectrum carbapenem antibiotic. The bactericidal activity of meropenem results born
the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and
Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets.
Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coil and Pseudomonas aeruginosa and PBPs 1,
2, and 4 of Staphylococcus aureus.
Meropenem has significant stability to hydrolysis by beta-lactamases of most categories, both perticillinases
and cephalosporinases produced by Gram-positive and Gram-negative bacteria.
Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-
resistant Staphylococcus epidermidis (MRSE). In vitro tests show that meropenem acts synergistically with
aminoglycoside antibiotics against some isolates of Pseudomonas aeruginosa.
Meropenem has been shown to be active against most isolates of the following microorganisms, both in vitro
and in clinical infections:
iv.) Gram-positive Bacteria
v.) Gram-negative Bacteria
Merocop is indicated for the treatment of the following infections in adults and children above 3 months
of age, when caused by susceptible bacteria:
• Pneumonia, including community-acquired pneumonia and nosocomial pneumonia
• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Intra- and post-partum infections
• Complicated skin and skin structure infections
• Broncho-pulmonary infections in cystic fibrosis
• Acute bacterial meningitis
Meropenem I.V. may be used in the management of neutropenic patients with fever that is suspected to
be due to a bacterial infection.
Meropenem I.V. has been found to be effective in eliminating concurrent bacteraemia in association with